➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Moodys

Last Updated: May 24, 2020

DrugPatentWatch Database Preview

RUVITE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Ruvite patents expire, and what generic alternatives are available?

Ruvite is a drug marketed by Savage Labs and is included in one NDA.

The generic ingredient in RUVITE is cyanocobalamin. There are nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.

US ANDA Litigation and Generic Entry Outlook for Ruvite

A generic version of RUVITE was approved as cyanocobalamin by WEST-WARD PHARMS INT on December 31st, 1969.

  Start Trial

Summary for RUVITE
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 31
Formulation / Manufacturing:see details
DailyMed Link:RUVITE at DailyMed
Drug patent expirations by year for RUVITE
Synonyms for RUVITE
13408-78-1
14463-33-3
18534-66-2
5,6-dimethyl-1-a-D-ribofuranosylbenzimidazole
5,6-dimethyl-1-alpha-delta-ribofuranosylbenzimidazole
68-19-9
AB2000361
AKOS015894306
alpha-(5,6-dimethylbenzimidazolyl)cobamide
B12r
B12s
C63H88CoN14O14P
CAS-68-19-9
Cbl
CCG-220433
CHEBI:16304
CHEBI:28911
CHEBI:60488
cob(I)alamin
Cob(II)alamin
Cob(III)alamin
cobalamin
Cobalamin (III)
Cobalamin;vitamin B-12;Cyanocobalamin
cobalamin(1+)
cobalamin(III)
Cobalamine
Cobinamide ion(1+) dihydrogen phosphate (ester) inner salt 3'-ester
Cobinamide ion(1+) dihydrogen phosphate (ester) inner salt 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosyl-1H-benzimidazole
Cobinamide,dihydrogenphosphate(ester),inner salt,3'-ester with(5,6-Dimethyl-1-a-d-ribofuranosyl-1H-benzimidazole-kn3),ion(1+)(9ci)
Cyanocob(III)alamin
cyanocobalamin
Cyanocobalamin;Cyanocob(III)alamin
DB00115
DSSTox_CID_24346
DSSTox_GSID_44346
DSSTox_RID_80159
DTXSID7044346
H486
HMS1569G08
HMS2096G08
HMS3713G08
Hydroxomin
NCGC00016302-01
NCGC00249888-01
Prestwick_564
Q55167869
Rubratope-57
Rubratope-60
Tox21_110358
Tox21_113664
V0344
vitamin B-12r
vitamin B12
Vitamin B12 (charged)
Vitamin B12 complex
Vitamin B12 NOS

US Patents and Regulatory Information for RUVITE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Savage Labs RUVITE cyanocobalamin INJECTABLE;INJECTION 080570-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.